Will ENDRA Life Sciences stock go up?

According to Danelfin AI, ENDRA Life Sciences has today an AI Score of 2/10 (Strong Sell rating), because its probability of beating the market in 3 months (41.87%) is -8.95% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for ENDRA Life Sciences stock?

The ENDRA Life Sciences target price is $25.35 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold ENDRA Life Sciences stock right now?

ENDRA Life Sciences has today a Strong Sell rating (AI Score 2/10), according to Danelfin AI. Its probability of beating the market in 3 months (41.87%) is -8.95% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether ENDRA Life Sciences stock is a good buy .

Is ENDRA Life Sciences undervalued right now?

Based on analysts, the average price target upside for ENDRA Life Sciences is +401.00% (1Y). According to Danelfin AI, ENDRA Life Sciences has today an AI Score of 2/10 (Strong Sell Rating).

What was the price range of ENDRA Life Sciences stock over the past 12 months?

The ENDRA Life Sciences stock price range over the past 12 months has been $3.19 - $8.84.

What is going on with ENDRA Life Sciences stock in the last 3 months?

The ENDRA Life Sciences stock performance in the last quarter has been +8.81%.

Does ENDRA Life Sciences offer dividend payments?

No, ENDRA Life Sciences does not currently pay dividends.

What is the current market capitalization of ENDRA Life Sciences?

ENDRA Life Sciences's market cap is $6.4M, as of 2026-07-02 08:00.

When is the next NDRA earnings report date?

NDRA will publish its next earnings report on 2026-05-18.

ENDRA Life Sciences Inc (NDRA) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

NDRA AI-Powered Stock Analysis

AI Score Explanation

AI Score

Strong Sell

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, ENDRA Life Sciences Inc today receives an AI Score of 2/10, which translates to a Sell rating. The stock has a 41% probability of outperforming the market in the next 3 months, which is 10% lower than the average probability of any stock (51%). The top positive contributors include Alpha Last Day (bottom 10% decile, impact +1.09%) and Alpha 1Y (top 20% decile, impact +0.80%), both boosting the probability. However, the strongest detractors are Chart Pattern (504d) (impact -1.72%), ATR (180d Volatility) (top 10% decile, impact -1.46%), and Beginning Cash (bottom 10% decile, impact -1.39%), which weigh heavily against the stock. Notable data points include the Fear & Greed Index at 31 (extreme fear), which negatively impacts the probability, and Institutional Ownership at 7.06% (bottom 20% decile), indicating low confidence from large investors. The stock also shows high volatility with Maximum Volatility in the top 10% decile and Normalized ATR (180d) in the top 10% decile, both detracting from the outlook. On the positive side, Alpha Last Day is in the bottom 10% decile but still contributes positively, suggesting a potential contrarian signal. Overall, the combination of weak fundamentals, high volatility, and negative technical patterns outweighs the few positive alpha signals, resulting in a low AI Score and a Sell rating.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Earnings Quality+0.59%
Stability and reliability of reported earnings
Growth+0.46%
Expected pace of revenue and earnings expansion

Volatility-3.02%
How much the stock price tends to fluctuate
Valuation-2.36%
How the stock is priced relative to its fundamentals
Sentiment-2.13%
How analysts and the market view the stock
Momentum-1.60%
Direction and strength of recent price movements
Size & Liquidity-0.89%
Company size and trading liquidity

NDRA probability advantage of beating the market (3M):

-8.95%

Technical

ENDRA Life Sciences (NDRA) has a Technical Score of 3/10 because, according to only technical analysis, it has a probability advantage of -6.07% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.64%) and the probability of NDRA (44.57%) of overperforming the market in the next 3 months, as determined by Danelfin AI’s technical analysis.

Average probability of any US-listed stock of beating the market (3M)50.64%
NDRA probability advantage of beating the market (only technical, 3M)-6.07%
NDRA probability of beating the market (3M)44.57%

NDRA probability advantage of beating the market (only technical, 3M): -6.07%

The AI-powered technical analysis of ENDRA Life Sciences (NDRA) is only based on the 30 technical features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of NDRA:

Type	Alpha Signal	Probability Advantage Impact (3M)
Technical	Upgrade to Pro to unlock	+2.04%
Technical	Upgrade to Pro to unlock	-1.93%
Technical	Upgrade to Pro to unlock	-1.84%
Technical	Upgrade to Pro to unlock	-1.73%
Technical	Upgrade to Pro to unlock	-1.69%
Technical	Upgrade to Pro to unlock	-1.66%
Technical	Upgrade to Pro to unlock	-1.61%
Technical	Upgrade to Pro to unlock	-1.60%
Technical	Upgrade to Pro to unlock	+1.40%
Technical	Upgrade to Pro to unlock	-1.22%
Technical	Upgrade to Pro to unlock	+1.11%
Technical	Upgrade to Pro to unlock	-1.10%
Technical	Upgrade to Pro to unlock	+1.10%
Technical	Upgrade to Pro to unlock	+1.03%
Technical	Upgrade to Pro to unlock	-0.89%

Rest of Alpha Signals: +2.53%

NDRA probability advantage of beating the market (only technical, 3M)Total:-6.07%
NDRA Technical Score

Significant changes Vs previous day

NDRA Short Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$5.06
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro)
Take Profit:$XXXXXPro (XXXXX
Pro
)

NDRA Proven Sell Signal & Price Forecast

This is the price chart for NDRA from January 2, 2026 until today. The chart indicates, in red, the 112 days when the stock received a Sell/Strong Sell rating (sell signals, AI Score 1 to 3).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Sell signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Sell signals

Forecast:

1 Month
3 Months
6 Months
1 Year

NDRA Average Past Performance & Loss Rate

Three months after its 2083 Sell signals since July 2026, NDRA had an average performance of xxxxxx and a xxxxxx Loss rate (negative performance).

2083 Past NDRA Sell Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				-44.89%
Average Alpha				-57.29%
Loss Rate (% Negative Perf.)				87.37%
% Negative Alpha				90.71%

NDRA Frequently Asked Questions

Will ENDRA Life Sciences stock go up?
According to Danelfin AI, ENDRA Life Sciences has today an AI Score of 2/10 (Strong Sell rating), because its probability of beating the market in 3 months (41.87%) is -8.95% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for ENDRA Life Sciences stock?
Is it a good time to buy, sell, or hold ENDRA Life Sciences stock right now?
Is ENDRA Life Sciences undervalued right now?
What was the price range of ENDRA Life Sciences stock over the past 12 months?
What is going on with ENDRA Life Sciences stock in the last 3 months?
Does ENDRA Life Sciences offer dividend payments?
What is the current market capitalization of ENDRA Life Sciences?
When is the next NDRA earnings report date?

ENDRA Life Sciences Inc Company Profile

ENDRA Life Sciences Inc. is a pioneer in enhancing clinical diagnostic ultrasound capabilities through innovative technology development. The firm specializes in thermo-acoustic enhanced ultrasound technology, a tool that propels sound waves to interact with body tissues, organs, and blood for various medical applications. It stands out as an instrumental player in the treatment of nonalcoholic fatty liver disease and is pivotal in areas like tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.

Moreover, ENDRA offers advanced diagnostic imaging technologies such as computed tomography (CT), magnetic resonance imaging (MRI), and additional ultrasound capabilities. These technologies revolutionize medical treatments by providing physicians with an inside view of the human body's intricacies from broken bones and cancers to indications of cardiovascular diseases or internal bleeding–equipping them with valuable insights about various medical conditions.

Endra maintains a fruitful research collaboration with General Electric Company, staging a platform for cutting-edge advancements in the field. Incorporated in 2007 and nestled at its base in Ann Arbor, Michigan, ENDRA Life Sciences Inc., prevails as an aspirational endeavor focused on unfolding transformative methodologies within healthcare diagnostics using sound wave interaction.

Sector:
Country:United States
Industry:
Address:3600 Green Ct Ste 350, Ann Arbor
Employees:21
Website:endrainc.com

Pros

Proprietary thermoacoustic ultrasound technology platform

Addressing unmet diagnostic need in liver disease

Non-invasive diagnostic method for patient comfort

Scalability potential of medical device sales

Established regulatory pathways for medical devices

Cons

High capital requirements for medical device development

Lengthy and uncertain regulatory approval process

Market adoption challenges for novel diagnostic tools

Competition from existing and emerging diagnostic methods

Dependence on clinical validation and reimbursement

NDRA Stock AI Analysis High Risk